Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPJOHN’s ROGAINE, CLEOCIN-T WILL BE PROMOTED BY OWEN/GALDERMA’s

Executive Summary

UPJOHN's ROGAINE, CLEOCIN-T WILL BE PROMOTED BY OWEN/GALDERMA's specialized dermatology sales force beginning Jan. 1, 1991. A Sept. 7 agreement will put Owen/Galderma's 57-person sales force behind the two Upjohn prescription lines in the dermatologist office market. Fort Worth-based Owen/Galderma, a subsidiary of Nestle's Alcon Labs U.S. drug business, currently markets several prescription products, including the Nutracort 1% hydrocortisone line, a benzoyl peroxide anti-acne line under the tradename Benzac, and Desowen .05% desonide topicals. In addition, Owen/Galderma markets OTC and ethical OTC products, such as Nutraderm moisturizing lotion, the liquid skin cleanser Cetaphil and the Ionil line of dandruff/psoriasis shampoos. Upjohn will continue to market the baldness product Rogaine and the Cleocin T anti-acne line to dermatologists via its 14-person Specialty Consultants group, created as part of the Upjohn Dermatology Division, until Owen/Galderma's promotional efforts begin. The Specialty Consultants group will then halt detailing to concentrate on the development of marketing techniques designed to help dermatologists expand their practices, Upjohn said. Upjohn created the Dermatology Division on Aug. 1 "to maximize Rogaine and Cleocin T opportunities and to actively pursue licensing opportunities, acquisitions or joint ventures in the field of dermatology," the release says. The Dermatology Division is headed by Keith Barton, formerly the executive director of the Rogaine Business Group. Upjohn will continue promoting Cleocin T and Rogaine to office-based physicians and other specialists through its prescription drug sales force. The company also has co-marketing agreements with Rorer for the anti-arthritis drug Ansaid (flurbiprofen) and the beta blocker celiprolol and co-promotes SmithKline Beecham's thrombolytic Eminase.
UsernamePublicRestriction

Register

PS018085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel